A Phase I, Double-Blind, Placebo-Controlled, Randomised, First in Human, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NYR-BI03 in Healthy Participants, When Administered as a 3-hour Infusion
Latest Information Update: 21 Apr 2025
At a glance
- Drugs NYR BI 03 (Primary)
- Indications Brain injuries; Stroke
- Focus Adverse reactions; First in man
- Sponsors Nyrada
- 28 Oct 2025 According to a Nyrada media release, the company is finalizing its submission to the Human Ethics Research Committee (HREC), a critical step towards commencing this clinical trial which is anticipated to begin in late 2024.
- 01 Apr 2025 New trial record
- 31 Mar 2025 According to a Nyrada media release, company announced that first cohort of patients has been dosed in this trial.